AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06394401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BAL:GLU+FRU
Description: 53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
Study NCT06394401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DEF:GLU
Description: 80 g glucose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
Study NCT06394401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DEF:GLU+FRU
Description: 53 g glucose plus 27 g fructose consumed during steady-state exercise following 48 hours of consuming an energy balance diet
Study NCT05938777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Stage-Matched Intervention
Description: The proposed intervention will be non-Stage-Matched that uses different Processes of Change as strategies to change the physical exercise behavior.
Study NCT05346783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJO-083
Description: Diquafosol ophthalmic sodium solution, 1 drop 3 times a day
Study NCT05346783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: 1 drop 6 times a day
Study NCT05346783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diquafosol ophthalmic sodium solution 3%
Description: Diquafosol ophthalmic sodium solution, 1 drop 6 times a day
Study NCT05336110 — intervention group
Intervention type: OTHER
Intervention: Postponing surgery
Description: Postponing surgery for patients with Sars-cov-2 infection
Study NCT04971213 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: Emergency and transport ventilator (Monnal T60, Airliquide, Antony, France)
Study NCT04971213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula heated and humidified oxygen
Description: AirVO2 device (Fisher and Paykel, New Zealand)
Study NCT05739292 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EuNmCV-5
Description: 0.5mL single intramuscular dose on Day 0
Study NCT05739292 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: 0.5mL single intramuscular dose on Day 0
Study NCT05476081 — intervention group
Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin (100-300 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study NCT04661904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Description: Our active treatment will consist of 600 pulses per session, delivered over the right dorsolateral prefrontal cortex at 80% of resting motor threshold (RMT). Every session cTBS consists of 50 Hz triplets of pulses delivered at 5 Hz for 40 seconds for a total of 600 pulses. Every set simulation includes 3 sessions. All enrolled patient in the cTBS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes during the hospitalization after the surgery. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
Study NCT04661904 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The sham stimulation group will receive a sham cTBS (600 pulses per session, 3 sessions per day, ISI ≥ 30mins, 4 days) with the coil set at 90 against the skull. The first set of stimulation will be given at 4 hours after the end of surgery on the day of surgery. The other sets of stimulation will be given at 8 am, 8:30 am and 9:00 am on postoperative day 1,2 and 3, respectively.
Study NCT05476081 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel
Description: Clopidogrel (75-600 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study NCT05476081 — intervention group
Intervention type: DRUG
Intervention: Ticagrelor
Description: Ticagrelor (90-180 mg) administered for 21-90 days in combination with another antiplatelet treatment
Study NCT06354855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group is doing breathing exercises while watching videos
Description: Group is doing breathing exercises while watching videos: A video consisting of 30-minute exercises will be shot for these patients. And each patient will be asked to do the breathing exercise for 30 minutes by watching this video.
Study NCT06354855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medium pace walking group
Description: Medium pace walking group: 30 minutes daily. Walking at a moderate pace is required. Physical activity levels will be monitored with the ActiGraph GT3X+ Accelerometer.
Study NCT06645886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQB198
Description: Oral KQB198
Study NCT06645886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Oral dasatinib
Study NCT05304585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05304585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT05304585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05304585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT05304585 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT05304585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI
Study NCT05103358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients
Study NCT06059560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Intensive nutritional therapy based on real world therapy
Study NCT05304585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT05304585 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation
Study NCT05304585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT03814135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hipnos 3
Description: 1 tablet, oral, once a day.
Study NCT03814135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hipnos 5
Description: 1 tablet, oral, once a day.
Study NCT03814135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hipnos 5 Placebo
Description: 1 tablet, oral, once a day.
Study NCT03814135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hipnos 5 Placebo
Description: 1 tablet, oral, once a day.
Study NCT03814135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hipnos 3 Placebo
Description: 1 tablet, oral, once a day.
Study NCT03814135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hipnos 3 Placebo
Description: 1 tablet, oral, once a day.
Study NCT04859192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gamified flipped classroom
Description: moodle will be gamified
Study NCT06604429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.
Study NCT06604429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: aerobic exercises in form of cycle ergometer training (Each girl started session with a 5 min of warm-up. The exercise phase is performed at 65-75% of age-predicted peak heart rate using an orbitrack device for 20 minutes). Finally, a 5 min cool-down period is permitted, the total session that would be applied about 30 min.
Study NCT06604429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Advice
Description: Adolescent girls participated in the study receive diet advices based on a balanced low calorie diet (1500 Kcal)
Study NCT06604429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Advice
Description: Adolescent girls participated in the study receive diet advices based on a balanced low calorie diet (1500 Kcal)
Study NCT06604429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise
Description: Virtual reality game exercise involves 25 min of exercise where adolescent girl immersed in the game and did physical activities for the upper and lower extremities according to the game's requirements, and finally a 5 min cool-down part to lower the heart rate and end the session with static flexibility routines, the total session that would be applied about 30 min of Virtual reality exercises.
Study NCT06397911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825
Description: The study treatment will be administered as 5 SC doses in total 12 weeks
Study NCT06397911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study treatment will be administered as 5 SC doses in total 12 weeks
Study NCT05961371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
Study NCT06622044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vision therapy group
Description: accommodation and vergence exercise
Study NCT06622044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prism
Description: wearing prism glasses
Study NCT06680921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0270
Description: Experimental
Study NCT06680921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus (Afinitor®)
Description: Experimental and Active comparator
Study NCT06680921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (Afinitor®)
Description: Experimental and Active comparator
Study NCT06680921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane tablets
Description: Active Comparator
Study NCT06680921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant injection
Description: Active Comparator
Study NCT05071352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nefopam
Description: Nefopam will be administered as an initial dose of 20 mg IV dose infused over 15 minutes then, as continuous infusion of 5 mg/hr for 24 hours.
Study NCT05071352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Description: In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
Study NCT05071352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care in the ICU for assessment and management of pain, sedation, and delirium.
Description: In our protocol we use analgiosedation approach (an opioid is used before a sedative to reach the sedation goal), targeting light sedation using richmond agitation sedation scale (RASS) score -1 to 0, and assess delirium using confusion assessment method for the ICU (CAM-ICU).
Study NCT05674201 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Propofol-Dexmedetomidine
Description: Propofol-Dexmedetomidine AND Propofol-Remifentanil
Study NCT06313177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: syndesmosis fixation with screws
Description: syndesmosis fixation with Syndesmotic screw in neutral position versus maximum ankle dorsiflexion in ankle fracture
Study NCT04603391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate plus Cannabidiol
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL Epidiolex® solution
Study NCT04603391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-Methylphenidate plus Cannabidiol Placebo solution
Description: Subjects will be administered one 10 mg tablet of dl-methylphenidate (Ritalin®) plus 7.5 mL of Epidiolex® placebo solution
Study NCT04980313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xenogenic collagen matrix
Description: Use of xenogenic collagen matrix for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
Study NCT04980313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous connective tissue graft
Description: Use of connective tissue graft for the maintenance of buccal soft tissues around immediate dental implantes into extraction sockets.
Study NCT05688319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Training
Description: Within the scope of the study, problem-solving training was conducted for the mothers in the experimental group in the study once a week for 10 weeks. The duration of each training session was 60-90 minutes.
Study NCT06480188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation
Description: Group A was the GPi-DBS stimulation group； Group B was the STN-DBS stimulation group
Study NCT05412199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percussion Massage Therapy
Description: Individuals in the percussion massage therapy group will get 3 minutes of percussion massage therapy on the hamstring and gastrocnemius muscles along the origo-insertion in the mid-frequency range.
Study NCT05412199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graston
Description: Instrument-assisted soft tissue mobilization will be used on the hamstring and gastrocnemius muscles along the 5-minute origo insertion line in the Graston group.
Study NCT05412199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching
Description: Dynamic stretching exercises for the hamstring and gastrocnemius muscles will be performed in the dynamic stretching exercise group.
Study NCT06335719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BES
Description: Nerve biopsies during surgery + brief electrical stimulation therapy
Study NCT06335719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of Care surgery
Description: Nerve biopsies during surgery - no brief electrical stimulation therapy
Study NCT06284642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urokinase
Description: On the basis of standard treatment for severe neurological conditions, within 24 hours of aneurysm treatment, lumbar drainage combined with intrathecal urokinase injection was started. 30,000 IU urokinase dissolved in 3 ml normal saline was injected into the subarachnoid space, 3 ml normal saline was rinsed into the tube, and the tube was clamped for observation for 2 hours, once a day, for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
Study NCT06284642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of standard treatment for severe neurological conditions, the treatment of lumbar drainage combined with intrathecal placebo saline injection was started within 24 hours after aneurysm treatment, 3 ml placebo was injected into the subarachnoid space, 3 ml normal saline was flushed into the tube, and the tube was observed for 2 hours, once a day for 3 consecutive days. Lumbar cisternae drainage Cerebrospinal fluid is slowly and steadily drained at a rate of less than 8ml/h per hour, the daily drainage volume is not more than 200 ml, and the drainage time of lumbar cisternae is controlled within 7 to 10 days, not more than 14 days.
Study NCT06248268 — intervention group
Intervention type: OTHER
Intervention: (Neuro-)psychological assessment
Description: The measurement, which takes place 1 week after the informed consent, aims to determine the distinct (neuro-) psychological patterns of suicidal behavior versus suicidal ideation, in comparison to two control groups.
Study NCT04801667 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavac
Description: The CoronaVac is manufactured by Sinovac Life Sciences Co., Ltd. This vaccine contains the inactivated SARS-CoV-2 virus antigen and is administered intramuscularly.
Study NCT04912336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard coagulation profile
Description: prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), the fibrinogen level, plateletcount
Study NCT04912336 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Specific coagulation tests
Description: AT III, anti Xa, ACT, ROTEM
Study NCT04912336 — intervention group
Intervention type: OTHER
Intervention: Bleeding Scores
Description: Global Utilization of Streptokinase and Tpa for Occluded arteries definition of bleeding (GUSTO) AND Bleeding Academic Research Consortium Definition for Bleeding (BARC)
Study NCT06617273 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ophthalmosurgical handpiece with active anterior chamber pressure sensing and regulation
Description: Cataract surgery in patients with diabetic retinopathy using active anterior chamber pressure sensing and regulation
Study NCT05736536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chance2Act
Description: A Health education package that has been developed based on Transtheoretical Model to encourage behaviour change for weight loss among overweight/obese type 2 diabetes adults.
Study NCT06339892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Determination of HCMV DNA in plasma after DNAse digestion.
Description: Plasma will be tested after DNAse digestion for quantification of virion-associated HCMV DNA (defined as true breakthrough HCMV productive infection).
Study NCT06339892 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Determination of HCMV DNA in blood or plasma.
Description: HCMV DNA will be determined in blood or plasma without DNAse digestion, as per current clinical practice.
Study NCT06624800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder chuna treatment(posterior displacement, anterior displacement, or lateral displacement)
Description: The Shoulder Chuna therapy for the shoulder joint will be performed on the affected shoulder from the second day of hospitalization until the day before discharge.
Study NCT06624800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study NCT06624800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Korean medical treatment
Description: acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
Study NCT06328127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PATH
Description: PATH, a phone-delivered positive psychology intervention for patients who have undergone HSCT, consists of three 3-week modules. The first module focuses on gratitude and physical activity goal setting. The second module focuses on personal strengths and resources to enhance daily physical activity. The third module focuses on meaning and assessing barriers to physical activity. The third week of each module is an integration exercise dedicated to help participants explore practical ways of incorporating the themes for the given module into daily life. A trained interventionist will guide participants to complete each 30-minute weekly session.
Study NCT06314763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20mg
Description: Single dose on day 1 and day 16
Study NCT06314763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib 960mg
Description: Daily dose from day 3 till day 16
Study NCT06327386 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FAPI#18F-FDG
Description: FAPI and FDG combined with PET/MR imaging in patients with gastric cancer after neoadjuvant therapy
Study NCT06432556 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: scRNAseq
Description: A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient)
Study NCT06432556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: two Skin biopsies
Description: 2 skin biopsies from a lesional area
Study NCT06432556 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: one Skin biopsies
Description: 1 skin biopsies from a lesional area
Study NCT05197478 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mini Nutritional Assessment ,Pıtsburg Sleep Qualıty Scale, Short Physical Activity Survey
Description: To evaluate the lifestyle before being infected with COVID 19, physical activity, nutrition and sleep habits were questioned.~To evaluate sleep habits; Pitsburg Sleep Quality Scale (PSQS) Nutritional habits: Mini Nutritional Assessment(MNA) Scale For the evaluation of physical activity; International Brief Physical Activity Questionnaire